Trump administration takes steps to allow cheaper drug imports from Canada
December 18, 2019Business Services Big Pharma, FDA, Trump, Trump Administraion, US Pharma
The Trump administration is close to allowing the import of some prescription Canadian drugs into the country.The FDA and the …
FDA advisory panel back Merck & Co.’s Keytruda treatment for bladder cancer
December 18, 2019Research and Development FDA, Merck, Merck and Co, NHS, NICE, keytruda
An FDA advisory committee voted 9 to 4 in favour of recommending Merk and Co’s Keytruda (pembrolizumab) for treatment in …
NHS Scotland gives green light to funding haemophilia A drug Hemlibra
December 18, 2019Research and Development NHS, haemophilia, haemophilia B, haemophilia a, nhs scotland
NHS Scotland has commissioned Hemlibra (emicizumab), by Chungai Pharma UK Ltd and Roche Products Ltd, to treat people with congenital …
Eli Lilly CEO says Elizabeth Warren’s claims they failed on cheaper insulin is ‘nonsense’
December 18, 2019Research and Development Bernie Sanders, Eli Lilly, Elizabeth Warren, US Pharma, US Presidential Election, insulin
David Ricks, the CEO of Eli Lilly, has said that Presidential candidate Senator Elizabeth Warren’s claims his company failed on …
FDA advisory committee approves the use of Lynparza in pancreatic cancer
December 18, 2019Research and Development AstraZeneca, Cancer, Merck, Pancreatic cancer, lynparza
The FDA’s Oncologic Drugs Advisory Committee (ODAC) has recommended the approval of AstraZeneca and Merck’s Lynparza (olaparib) to treat pancreatic …
Novartis abandons asthma drug after Phase 3 trial results
December 17, 2019Manufacturing and Production Novartis, Novartis. R&D, asthma, novartis r&d
Novartis have said it is not going forward with a new asthma drug, as the treatement failed its Phase 3 …
Irish haemophilia A patients to get continued access to Sobi’s extended half-life factor replacement therapy
December 17, 2019Manufacturing and Production haemophilia, haemophilia B, haemophilia a
The Republic of Ireland’s Haemophilia Product Selection and Monitoring Advisory Board (HPSMAB) and Sobi United Kingdom and Republic of Ireland, …
Sackler family withdrew $10 billion from Purdue Pharma while legal pressure mounted, audit shows
December 17, 2019Manufacturing and Production Oxy, OxyContin, Purdue Pharma, Sackler family, opioid, opioid crisis, sackler
An audit commissioned by Purdue Pharma, to help navigate its bankruptcy, indicates that members of the Sackler family withdrew $10.7 …
FDA approves Pfizer and Astellas Pharma’s prostate cancer drug
December 17, 2019Manufacturing and Production Astellas Pharma, Cancer, FDA, Pfizer, Xtandi, prostate cancer
The FDA has approved Pfizer and Astellas Pharma’s Xtandi (enzalutamide) to treat patients with a type of prostate cancer. The …
British Pharmacists call for regulation on non-medicinal CBD products
December 17, 2019Manufacturing and Production CBD, CBD Oil, CBD Products, cannabis
Pharmacists are calling for more checks on products containing Cannabis derivative cannabidiol (CBD) that are sold in shops across the …
Roche’s Tecentriq combo boosts progression-free survival in previously untreated BRAF V600 mutation-positive advanced melanoma
December 16, 2019Manufacturing and Production, Research and Development, Sales and Marketing Roche, melanoma, pharma, tecentriq
Roche has lifted the curtain on new Phase 3 data for its immunotherapy Tecentriq (atezolizumab), confirming that the therapy, when …
A new weapon against Parkinson’s-related psychosis
December 16, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Parkinson's disease, cannabidiol, cannabis, feature, pharma
Dr Arthur Roach, Director of Research at the charity Parkinson’s UK, discusses new trials on cannabidiol in the treatment of …
Transgene ceases development of failed advanced non-squamous non-small cell lung cancer immunotherapy candidate
December 16, 2019Research and Development, Sales and Marketing Cancer, Transgene, lung cancer, pharma
Cancer immunotherapeutics firm Transgene has confirmed that it is to terminate further development of its TG4010 candidate in the first-line …
Novartis pulls fevipiprant development in asthma following trial failure
December 16, 2019Research and Development, Sales and Marketing Fevipiprant, Novartis, asthma, pharma, trial failure
Novartis has made it known that its DP2 receptor antagonist fevipiprant failed at Phase 3 to show clinically relevant levels …
NICE reverses previous decision to recommend Vifor Pharma’s Veltassa for NHS treatment of hyperkalaemia
December 16, 2019Sales and Marketing NHS, NICE, Veltassa, Vifor pharma
It has emerged that NICE has awarded its recommendation to Vifor Pharma’s Veltassa (patiromer) for treating hyperkalaemia, a condition classified …
Biogen terminates gosuranemab in progressive surpanuclear palsy following Phase 2 failure
December 16, 2019Research and Development, Sales and Marketing Biogen, pharma, trial failure
Biogen has revealed its intention to shut down further development of gosuranemab after results of a Phase 2 study showed …
Pfizer’s Vyndaqel scores CHMP support for transthyretin amyloidosis in cardiomyopathy patients
December 16, 2019Sales and Marketing Pfizer, Vyndaqel, pharma
Pfizer’s once-daily 61mg oral capsule formulation of Vyndaqel (tafamidis) has secured a positive opinion from the European Medicines Agency’s (EMA) …
Genmab’s Darzalex secures CHMP recommendation in Europe for front-line multiple myeloma
December 13, 2019Medical Communications, Sales and Marketing CHMP, Genmab, darzalex, pharma
The Committee for Medicinal Products for Human Use (CHMP), an advisory panel for the European Medicines Agency, has given its …
Top Ten most popular articles on Pharmafile.com this week
December 13, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing pharma, top ten
As the UK reels from the news that Boris Johnson and the Conservative Party have stormed the general election and …
Novartis’ Beovu scores CHMP recommendation after proving non-inferior to Eylea in wet age-related macular degeneration
December 13, 2019Medical Communications, Sales and Marketing Beovu, EMA, Novartis, pharma
Novartis’ single-chain antibody fragment Beovu has secured recommendation from the European Medicines Agency’s Committee for Medicinal Products for Human Use …
Latest content
Five Facts about NHS and primary care
AI in pharma: From lab development to patient impact
